AstraZeneca to invest $2.5 billion in new global strategic R&D centre in China
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
Such combined efficacy (achieving clinical cure and microbiologic cure) of Zaynich is highest ever among all the FDA-approved novel antibiotics developed in the last more than 10 years
He has 29+ years’ comprehensive experience in world-class Formulations and API (for US and EU requirements) mainly related to injectables
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
The session focused on “Biomanufacturing of Enzymes,” a critical domain under the BioE3 Policy.
Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
Subscribe To Our Newsletter & Stay Updated